To date, it has not been determined whether FGF21 based therapy, often deemed to correct hyperglycemia via an insulin sensitization mechanism [6], remains efficacious with regard to glucose endpoints in the context of low insulin levels. The gene discussed is FGF21; the disease is Hyperglycemia.